Fasce E, Román O, Zárate H, Prat H
Facultad de Medicina, Universidad de Concepción, Chile.
Rev Med Chil. 1997 Jan;125(1):23-9.
In the last two decades, angiotensin converting enzyme inhibitors have become first line medications in the treatment of hypertension.
To assess the tolerance and effectiveness of ramipril as monotherapy in the treatment of essential hypertension.
One hundred eighty eight hypertensive patients, aged 21 to 80 years-old, coming from 4 Chilean hospitals were studied. Using an open non controlled design; they were treated with placebo for two weeks and with the active drug during eight weeks, in initial doses of 2.5 mg/day that were adjusted to 5 mg/day if diastolic blood pressure did not drop below 90 mm Hg or if its reduction was less than 10 mm Hg.
During the active drug treatment period, systolic blood pressure decreased from 164.8 +/- 7.2 to 147.3 +/- 4.8 mm Hg. Diastolic blood pressure dropped from 102.3 +/- 3.1 to 87.8 +/- 3.0 mm Hg. Seventy percent of patients achieved a diastolic blood pressure of less than 90 mm Hg, 56.9% with 2.5 mg/day and 13.8% with 5 mg/day. Dizziness, cough and headache were the main adverse reactions, observed in 3.7, 3.2 and 2.1% of patients respectively. Adherence to treatment was 98%. There were no changes in laboratory values during the treatment period.
Ramipril is effective and well tolerated in the treatment of essential hypertension.
在过去二十年中，血管紧张素转换酶抑制剂已成为治疗高血压的一线药物。
评估雷米普利单药治疗原发性高血压的耐受性和有效性。
对来自智利4家医院的188例年龄在21至80岁之间的高血压患者进行了研究。采用开放非对照设计；他们先接受两周的安慰剂治疗，然后接受八周的活性药物治疗，初始剂量为2.5毫克/天，如果舒张压未降至90毫米汞柱以下或降低幅度小于10毫米汞柱，则将剂量调整为5毫克/天。
在活性药物治疗期间，收缩压从164.8±7.2毫米汞柱降至147.3±4.8毫米汞柱。舒张压从102.3±3.1毫米汞柱降至87.8±3.0毫米汞柱。70%的患者舒张压降至90毫米汞柱以下，其中2.5毫克/天剂量组为56.9%，5毫克/天剂量组为13.8%。头晕、咳嗽和头痛是主要不良反应，分别在3.7%、3.2%和2.1%的患者中观察到。治疗依从性为98%。治疗期间实验室值无变化。
雷米普利治疗原发性高血压有效且耐受性良好。
